Study authors conducted a global, open-label, phase 3 study to report the safety and efficacy of ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD).
All articles by Chen Fang
In a study presented at ACTRIMS Forum 2023, researchers assessed the efficacy of treatment regimens on disability outcomes of patients with NMOSD- and MOGAD-optic neuritis and myelitis.
By
Publish Date
-
Latest News Your top articles for Friday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses